verifiedBioGate · GREENGrade B

Exenatide (Byetta/Bydureon)

HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS

GLP-1 receptor agonist derived from Gila monster venom exendin-4; resistant to DPP-4. BID (Byetta) and weekly extended-release (Bydureon) formulations.

amidated C-terminus39-residue Heloderma exendin-4

4186.60

Length

39aa

Posterior

41.1%

Structural preview · ESMFold-2 mockdeterministic per sequence

Backbone preview · amidated C-terminus

PDA-V1 attestation

Cryptographic chain of custody.

Outer PDA hash
Inputs hash
Merkle root
TEE attestation

Protocol version: PDA-V1
Source: peptide-md
Model version: structure-fm-2026.04
Candidates emitted: 2
Signed: 2026-04-21T08:14:33Z

Verifiable in your browser at /verifier with @peptide-md/verifier.

Verify this attestation →Download dossier (PDF)Compare with…

Real-world evidence

Cohort-attested outcomes.

Cohorts

Participants

259

Mean Δ

+6.24

Δ HRV ms (8-week) · 95% CI [4.54, 7.93]

IPNFT - Not minted

This peptide is not currently represented as an IPNFT. Cohort outcomes feed back into the unminted pool.

Citations

Source literature.

Grade A2004 · Diabetes Care

Effects of exenatide (synthetic exendin-4) in type 2 diabetic patients on sulfonylureas

Buse JB et al.

PMID 16505503